Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
NCT01962636 · Masonic Cancer Center, University of Minnesota · NA · terminated · last registry update 2026-05-20 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No longer a research question to answer.” | – | Registry record, Masonic Cancer Center, University of Minnesota |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPIA in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-26Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cyclosporine + Mycophenolate Mofetil (NCT03434730)
- 2026-05-14Results posted on the registry: Fred Hutchinson Cancer Center, Cyclophosphamide + Cyclosporine (NCT03246906)
- 2026-05-14Also stopped (terminated): Fred Hutchinson Cancer Center, Cyclophosphamide + Cyclosporine (NCT03246906)
- 2026-01-26Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Cyclosporine A (CsA) + Sirolimus (NCT07366801)
- 2025-08-26Results posted on the registry: Masonic Cancer Center, University of Minnesota, filgrastim + busulfan (NCT00357565)
- 2025-07-10Phase 3 first posted: Shanxi Bethune Hospital, Induction Therapy Regimen + Pre-Treatment Regimen (NCT07059156)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision